BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19881236)

  • 1. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
    Kanazawa I; Yamaguchi T; Yamauchi M; Sugimoto T
    Intern Med; 2009; 48(21):1869-73. PubMed ID: 19881236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
    Torimoto K; Okada Y; Mori H; Hajime M; Tanaka K; Kurozumi A; Narisawa M; Yamamoto S; Arao T; Matsuoka H; Inokuchi N; Tanaka Y
    Lipids Health Dis; 2013 Sep; 12():137. PubMed ID: 24053480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Ju SH; Lim JY; Song M; Kim JM; Kang YE; Yi HS; Joung KH; Lee JH; Kim HJ; Ku BJ
    Front Endocrinol (Lausanne); 2024; 15():1336357. PubMed ID: 38586464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
    Yamazaki D; Ishida M; Watanabe H; Nobori K; Oguma Y; Terata Y; Koyama T; Iino K; Kosaka T; Ito H
    Lipids Health Dis; 2013 Feb; 12():9. PubMed ID: 23374898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
    Moutzouri E; Liberopoulos EN; Tellis CC; Milionis HJ; Tselepis AD; Elisaf MS
    Atherosclerosis; 2013 Nov; 231(1):8-14. PubMed ID: 24125402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).
    Muntoni S; Pisciotta L; Muntoni S; Bertolini S
    J Clin Lipidol; 2015; 9(1):103-6. PubMed ID: 25670367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.
    Ason B; Tep S; Davis HR; Xu Y; Tetzloff G; Galinski B; Soriano F; Dubinina N; Zhu L; Stefanni A; Wong KK; Tadin-Strapps M; Bartz SR; Hubbard B; Ranalletta M; Sachs AB; Flanagan WM; Strack A; Kuklin NA
    J Lipid Res; 2011 Apr; 52(4):679-87. PubMed ID: 21262787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
    Catapano A; Brady WE; King TR; Palmisano J
    Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
    Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Clin Biochem; 2011 Jun; 44(8-9):627-34. PubMed ID: 21349260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
    Degli Esposti L; Sangiorgi D; Arca M; Vigna GB; Budal S; Degli Esposti E
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):160-7. PubMed ID: 22567731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.